IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene DBC1 Ensembl ENSG00000078725 Chromosome 9 Start 120968728 End 121171566
Description Deleted in bladder cancer protein 1 Precursor (Protein FAM5A) [Source:UniProtKB/Swiss-Prot;Acc:O60477]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 2687
     Entrez Gene : 1620
     UCSC : uc004bkc.2
     GeneCards : 2687
     RefSeq : NM_014618
     CCDS : CCDS6822.1
     Uniprot : O60477
     Interpro : O60477
     OMIM : 602865
     GeneTests : DBC1
     CGAP : DBC1
     PMID : 9175739

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  40292_at  0.14  5.99e-1  6.92e-1  -0.50  9.93e-2  1.63e-1
 HG_U133A  205818_at  -0.53  9.71e-6  2.26e-5  -1.99  9.93e-25  1.55e-24
 HG_U133_Plus2  1555457_at  0.10  5.91e-1  6.70e-1  0.03  8.94e-1  9.14e-1
 HG_U133_Plus2  205818_at  0.16  4.89e-1  5.77e-1  0.14  5.67e-1  6.23e-1
 Agilent_HS_21.6K  7888  0.05  9.54e-2  2.28e-1  0.05  2.43e-2  7.16e-2
 Agilent_HS_21.6K  8189  -0.07  4.46e-1  6.28e-1  -0.10  1.65e-1  2.99e-1

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  205818_at  -0.06  8.93e-1  9.93e-1  0.02  9.42e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 40292_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 205818_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 1555457_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 205818_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 7888    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 8189    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
dbccr1 bladder tumor We have investigated three candidate tumor suppressor genes on chromosome 9 (CDKN2A, DBCCR1, and TSC1), at the DNA level and by expression analysis in a panel of bladder tumor cell lines, many of which have probable LOH along the length of the chromosome, 11921286 Human
dbccr1 tumor We have investigated three candidate tumor suppressor genes on chromosome 9 (CDKN2A, DBCCR1, and TSC1), at the DNA level and by expression analysis in a panel of bladder tumor cell lines, many of which have probable LOH along the length of the chromosome, 11921286 Human
dbccr1 transitional cell carcinoma A new cell line, DSH1, derived from a pT1G2 transitional cell carcinoma with known homozygous deletion of DBCCR1, is described. 11921286 Human
dbc1 tumour Patient DNA was microdissected and extracted from archival tissue sections and analysed for loss of heterozygosity (LOH) at three regions on chromosome 9 where tumour suppressor genes (TSGs) are known to reside (INK 4A, DBC1, and TSC1). 11920732 Human
dbc1 tumours Levels of LOH at DBC1 or INK 4A were not significantly different in NR tumours than in REC primary tumours and recurrence-free survival was not affected by loss of either of these genes. 11920732 Human
dbc1 primary tumours Levels of LOH at DBC1 or INK 4A were not significantly different in NR tumours than in REC primary tumours and recurrence-free survival was not affected by loss of either of these genes. 11920732 Human
dbccr1 bladder cancer PURPOSE: The function of the tumor suppressor gene DBCCR1 (deleted in bladder cancer chromosome region 1) is unknown despite data supporting an important role for DBCCR1 in bladder tumorigenesis. 12442002 Human
dbccr1 tumor PURPOSE: The function of the tumor suppressor gene DBCCR1 (deleted in bladder cancer chromosome region 1) is unknown despite data supporting an important role for DBCCR1 in bladder tumorigenesis. 12442002 Human
dbccr1 bladder tumor Transient transfection of bladder tumor cell lines showed that DBCCR1 over expression in human bladder tumor cells results in the up-regulation of ASML3a RNA and protein expression. 12442002 Human
dbccr1 bladder cancer To understand the role of hypermethylation in TCC, we evaluated the methylation status of 20 CpG sites of the DBCCR1 5'-CpG island region in a total of 69 tumours from 45 patients, 21 normal urothelial specimens, and six bladder cancer cell lines. 11313984 Human
dbccr1 tumours To understand the role of hypermethylation in TCC, we evaluated the methylation status of 20 CpG sites of the DBCCR1 5'-CpG island region in a total of 69 tumours from 45 patients, 21 normal urothelial specimens, and six bladder cancer cell lines. 11313984 Human
dbccr1 bladder cancer PURPOSE: To better define cytogenetic mechanisms of CDKN2 loss at 9p21 and of DBCCR1 loss at 9q33 in bladder cancer, and to determine correlation with p53 and pRb. 11410506 Human
dbccr1 tumor Although the observed homozygous deletions strengthen the hypotheses that CDKN2 and DBCCR1 are important tumor suppressor genes, there is no evidence that either is a more critical or an earlier target for oncogenesis. 11410506 Human
dbccr1 bladder tumour Negative regulation of G(1)/S transition by the candidate bladder tumour suppressor gene DBCCR1. 11420708 Human
dbccr1 bladder cancer DBCCR1 (deleted in bladder cancer chromosome region candidate 1) maps to the chromosome region 9q32-33, a candidate tumour suppressor locus for bladder cancer. 11420708 Human
deleted in bladder cancer chromosome region candidate 1 bladder cancer DBCCR1 (deleted in bladder cancer chromosome region candidate 1) maps to the chromosome region 9q32-33, a candidate tumour suppressor locus for bladder cancer. 11420708 Human
dbccr1 tumour DBCCR1 (deleted in bladder cancer chromosome region candidate 1) maps to the chromosome region 9q32-33, a candidate tumour suppressor locus for bladder cancer. 11420708 Human
deleted in bladder cancer chromosome region candidate 1 tumour DBCCR1 (deleted in bladder cancer chromosome region candidate 1) maps to the chromosome region 9q32-33, a candidate tumour suppressor locus for bladder cancer. 11420708 Human
dbccr1 bladder cancer Although no mutations of DBCCR1 have been detected in bladder tumours, expression of DBCCR1 is silenced by promoter hypermethylation in 50% of bladder cancer cell lines analysed. 11420708 Human
dbccr1 bladder tumours Although no mutations of DBCCR1 have been detected in bladder tumours, expression of DBCCR1 is silenced by promoter hypermethylation in 50% of bladder cancer cell lines analysed. 11420708 Human
dbccr1 tumour Here we sought to provide functional evidence to authenticate DBCCR1 as a tumour suppressor using gene-transfer methods. 11420708 Human
dbccr1 bladder cancer These results demonstrate a role for DBCCR1 in cell cycle control, thereby supporting the hypothesis that this is the tumour suppressor gene targeted by 9q32-33 deletion in bladder cancer. 11420708 Human
dbccr1 tumour These results demonstrate a role for DBCCR1 in cell cycle control, thereby supporting the hypothesis that this is the tumour suppressor gene targeted by 9q32-33 deletion in bladder cancer. 11420708 Human
dbccr1 primary bladder cancers This interval overlaps part of a common region of deletion observed in a number of primary bladder cancers; moreover, the DNA sequence within the 1-Mb segment corresponds to part of a YAC genomic clone that encompasses a putative tumor suppressor gene, DB 11450846 Human
dbccr1 tumours No mutations were identified in the candidate tumour suppressor gene DBCCR1 in three tumours showing restricted LOH at 9q32-33. 22% of the specimens had HD at CDKN2A, but no HD was found on 9q. 11747331 Human
dbccr1 tumour No mutations were identified in the candidate tumour suppressor gene DBCCR1 in three tumours showing restricted LOH at 9q32-33. 22% of the specimens had HD at CDKN2A, but no HD was found on 9q. 11747331 Human
dbccr1 tumour CONCLUSIONS: Our observation of relatively frequent minor LOH at 9p22.1, 9q22.3 and 9q32-33.1 identifies regions within which putative tumour suppressor genes, including the PTCH and the DBCCR1 genes, may reside. 12745717 Human
dbc1 tumor A sequence-ready 840-kb PAC contig spanning the candidate tumor suppressor locus DBC1 on human chromosome 9q32-q33. 10444335 Human
dbc1 bladder cancer A putative tumor suppressor locus involved in bladder cancer has been mapped to human chromosome 9q32-q33 and designated DBC1. 10444335 Human
dbccr1 bladder cancer Chromosome 9, which is often partially or fully reduced to homozygosity in bladder cancer cells, harbors several tumor suppressor loci including deleted in bladder cancer chromosome region 1 (DBCCR1) at 9q32-33. 14712213 Human
dbccr1 tumor Chromosome 9, which is often partially or fully reduced to homozygosity in bladder cancer cells, harbors several tumor suppressor loci including deleted in bladder cancer chromosome region 1 (DBCCR1) at 9q32-33. 14712213 Human
dbccr1 bladder cancer Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. 9545632 Human
dbccr1 tumor Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. 9545632 Human
dbc1 bladder cancer This locus has been designated DBC1 (for deleted in bladder cancer gene 1). 9545632 Human
dbccr1 bladder cancer Although DBCCR1 was expressed in multiple normal human tissues including urothelium, mRNA expression was absent in 5 of 10 (50%) bladder cancer cell lines. 9545632 Human
dbc1 non-small cell lung cancers Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. 15746151 Human
dbc1 non-small cell lung cancers Genome-wide screening of DNA copy number aberrations in 27 cell lines derived from non-small cell lung cancers (NSCLCs), using a custom-made comparative genomic hybridization (CGH)-array, identified a homozygous deletion of the deleted in bladder cancer 1 15746151 Human
dbc1 tumors Homozygous deletion of DBC1, located at 9q33.1, was also observed in two of 53 primary NSCLC tumors examined. 15746151 Human
dbc1 nsclc Homozygous deletion of DBC1, located at 9q33.1, was also observed in two of 53 primary NSCLC tumors examined. 15746151 Human
dbc1 urothelial cancers Hypermethylation in part of a CpG island around the exon 1 of DBC1 has been reported in urothelial cancers, but the potential association between methylation and expression status was never clarified in that disease. 15746151 Human
dbc1 tumor Among our primary NSCLC cases, methylation of the DBC1 promoter occurred more frequently in men, elderly patients and smokers than in women, younger patients and nonsmokers respectively, but it was not correlated with tumor stage or histology. 15746151 Human
dbc1 nsclc Among our primary NSCLC cases, methylation of the DBC1 promoter occurred more frequently in men, elderly patients and smokers than in women, younger patients and nonsmokers respectively, but it was not correlated with tumor stage or histology. 15746151 Human
dbc1 nsclc Exogenous overexpression of DBC1 in NSCLC cell lines lacking its expression inhibited cell growth. 15746151 Human
dbc1 tumor Our results provide the first evidence that DBC1 is a likely tumor suppressor for NSCLC; silencing of the gene through homozygous deletion or methylation of its promoter region may be associated with progression of this disease. 15746151 Human
dbc1 nsclc Our results provide the first evidence that DBC1 is a likely tumor suppressor for NSCLC; silencing of the gene through homozygous deletion or methylation of its promoter region may be associated with progression of this disease. 15746151 Human
dbccr1 bladder tumour Exogenous expression of DBCCR1 protein or an HA epitope-tagged fusion protein, HA-DBCCR1 in NIH3T3 cells and human bladder tumour cell lines resulted in suppression of proliferation. 11420708 Human
dbccr1 hcc In comparison with the normal liver tissues from the healthy donors, it was found that while remained unmethylated the ABL, CAV, EPO, GATA3, LKB1, NEP, NFL, NIS and p27KIP1 genes, varying extents of the HCC specific hypermethylation were found associated 14672555 Human
dbccr1 hcc Judged by whether the hypermethylated occurred in HCC more frequently than in their neighboring normal tissues, the hypermethylation status of the AR, DBCCR1, IRF7, OCT6, and p73 genes was considered as the event specific to the late stage, while that the 14672555 Human
dbccr1 bladder tumor DBCCR1 mediates death in cultured bladder tumor cells. 14712213 Human
dbccr1 bladder tumor To understand the fate of DBCCR1-expressing cells, human bladder tumor cells were transiently transfected with an expression vector containing DBCCR1 fused to enhanced green fluorescent protein (EGFP). 14712213 Human
dbccr1 oral squamous-cell carcinoma Loss of heterozygosity at 9q33 and hypermethylation of the DBCCR1 gene in oral squamous cell carcinoma. 15226771 Human
dbccr1 tumour The DBCCR1 gene at chromosome 9q33 has been identified as a candidate tumour suppressor, which is frequently targeted by promoter hypermethylation in bladder cancer. 15226771 Human
dbccr1 bladder cancer The DBCCR1 gene at chromosome 9q33 has been identified as a candidate tumour suppressor, which is frequently targeted by promoter hypermethylation in bladder cancer. 15226771 Human
dbccr1 oral squamous-cell carcinoma Here, we studied the possible involvement of DBCCR1 in the development of oral squamous cell carcinoma. 15226771 Human
dbccr1 tumours DNA from 34 tumours was examined for loss of heterozygosity (LOH) at three markers surrounding DBCCR1 and for hypermethylation of the DBCCR1 promoter, using methylation-specific PCR and methylation-specific melting-curve analysis. 15226771 Human
dbccr1 tumours Hypermethylation of DBCCR1 was also present in three of seven epithelial tissues adjacent to the tumours, including two hyperplastic and one histologically normal epithelia. 15226771 Human
dbccr1 hyperplastic Hypermethylation of DBCCR1 was also present in three of seven epithelial tissues adjacent to the tumours, including two hyperplastic and one histologically normal epithelia. 15226771 Human
dbccr1 oral leukoplakias Furthermore, of four oral leukoplakias with dysplasia, one showed LOH at 9q33 and two showed DBCCR1 hypermethylation. 15226771 Human
dbccr1 astrocytoma Of the astrocytoma associated hypermethylated genes, the methylation pattern of the CDH13, cyclin a1, DBCCR1, EPO, MYOD1, and p16INK4a genes changed in no more than 5.66% (3/53) of astrocytoma tissues compared to non-astrocytoma controls, while the RASSF1 15367334 Human
dbccr1 tumor The genes associated with bladder carcinogenesis include oncogenes (such as H-ras, FGFR3, erbB2, CCND1, mdm2), tumor suppressor genes (such as INK4A/ARF, Rb, TP53, PTEN, TSC1, PTCH, DBCCR1), and DNA mismatch repair genes, etc. 12561447 Human
dbccr1 astrocytoma Low expression but infrequent genomic loss of the putative tumour suppressor DBCCR1 in astrocytoma. 15643521 Human
dbccr1 tumour Low expression but infrequent genomic loss of the putative tumour suppressor DBCCR1 in astrocytoma. 15643521 Human
dbccr1 transitional cell carcinomas of the urinary bladder DBCCR1 (deleted in bladder cancer chromosomal region 1) has been reported as the gene functionally affected by frequent loss of 9q32-33 in transitional cell carcinomas of the urinary bladder. 15643521 Human
dbccr1 bladder cancer DBCCR1 (deleted in bladder cancer chromosomal region 1) has been reported as the gene functionally affected by frequent loss of 9q32-33 in transitional cell carcinomas of the urinary bladder. 15643521 Human
dbccr1 tumours For these particular tumours, its proposed role in tumour suppression is supported both by the observation of methylation-based silencing of DBCCR1 in a large fraction of bladder cancers and by re-expression studies in bladder cancer-derived cell lines. 15643521 Human
dbccr1 tumour For these particular tumours, its proposed role in tumour suppression is supported both by the observation of methylation-based silencing of DBCCR1 in a large fraction of bladder cancers and by re-expression studies in bladder cancer-derived cell lines. 15643521 Human
dbccr1 bladder cancers For these particular tumours, its proposed role in tumour suppression is supported both by the observation of methylation-based silencing of DBCCR1 in a large fraction of bladder cancers and by re-expression studies in bladder cancer-derived cell lines. 15643521 Human
dbccr1 tumour A more general involvement of DBCCR1 in tumour development might be inferred from recent chip-based expression studies in other tumours. 15643521 Human
dbccr1 other tumours A more general involvement of DBCCR1 in tumour development might be inferred from recent chip-based expression studies in other tumours. 15643521 Human
dbccr1 gliomas The present study addressed expression of DBCCR1 in gliomas, specifically in astrocytomas, using semi-quantitative RT-PCR on 25 tumours of different malignancy grade and on 5 control brain tissue samples. 15643521 Human
dbccr1 tumours The present study addressed expression of DBCCR1 in gliomas, specifically in astrocytomas, using semi-quantitative RT-PCR on 25 tumours of different malignancy grade and on 5 control brain tissue samples. 15643521 Human
dbccr1 astrocytomas The present study addressed expression of DBCCR1 in gliomas, specifically in astrocytomas, using semi-quantitative RT-PCR on 25 tumours of different malignancy grade and on 5 control brain tissue samples. 15643521 Human
dbccr1 malignancy The present study addressed expression of DBCCR1 in gliomas, specifically in astrocytomas, using semi-quantitative RT-PCR on 25 tumours of different malignancy grade and on 5 control brain tissue samples. 15643521 Human
dbccr1 astrocytic tumours Genomic deletion of the DBCCR1 locus at 9q32-33 was also investigated, together with the CDKN2A locus at 9p21, by loss of heterozygosity analysis in a second series of 26 astrocytic tumours. 15643521 Human
dbccr1 tumour We found that DBCCR1 mRNA expression is markedly reduced in the majority of tumour samples compared to controls, and that this reduction significantly correlates with tumour grade. 15643521 Human
dbccr1 tumours Genomic loss of the DBCCR1 region was found in only 5 of 24 (21%) informative samples, with no obvious correlation to tumour grade, while loss of the CDKN2A locus was observed in 13 of 21 (62%) informative samples with high-grade tumours being affected mo 15643521 Human
dbccr1 tumour Genomic loss of the DBCCR1 region was found in only 5 of 24 (21%) informative samples, with no obvious correlation to tumour grade, while loss of the CDKN2A locus was observed in 13 of 21 (62%) informative samples with high-grade tumours being affected mo 15643521 Human
dbccr1 astrocytomas In contrast to the situation in bladder cancer, the prevalent inactivation of DBCCR1 seen at the expression level in astrocytomas is not primarily caused by genomic loss of the gene. 15643521 Human
dbccr1 bladder cancer In contrast to the situation in bladder cancer, the prevalent inactivation of DBCCR1 seen at the expression level in astrocytomas is not primarily caused by genomic loss of the gene. 15643521 Human
dbccr1 tumour Our findings support a more general role for DBCCR1 in tumour suppression with mechanisms of inactivation differing between tumour types. 15643521 Human
dbccr1 tumor All shared INK4a/ARF gene locus deletion and epigenetic silencing of the DBCCR1 tumor suppressor gene. 15833842 Human
deleted in bladder cancer 1 non-small cell lung cancers Genome-wide screening of DNA copy number aberrations in 27 cell lines derived from non-small cell lung cancers (NSCLCs), using a custom-made comparative genomic hybridization (CGH)-array, identified a homozygous deletion of the deleted in bladder cancer 1 15746151 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.